



TRANSMITTAL FORM

Express Mail Mailing Label No.: EV797329374US

Application Serial Number	09/754,831
Filing Date	January 3, 2001
First Named Inventor	Oppermann
Group Art Unit	1646
Examiner Name	Kemmerer, Elizabeth
Attorney Docket No.	STK-008CN
Patent No.	Not applicable
Issue Date	Not applicable

ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Check Attached <input type="checkbox"/> Copy of Fee Transmittal Form <input type="checkbox"/> Amendment/Response <input type="checkbox"/> Preliminary <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Letter to Official Draftsperson including Drawings [Total Sheets ____] <input type="checkbox"/> Petition for Extension of Time <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Form PTO-1449 <input type="checkbox"/> Copies of IDS Citations <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Sequence Listing submission <input type="checkbox"/> Paper Copy/CD <input type="checkbox"/> Computer Readable Copy <input type="checkbox"/> Statement verifying identity of above	<input type="checkbox"/> Copy of Notice to File Missing Parts of Application <input type="checkbox"/> Formal Drawing(s) <input type="checkbox"/> Request For Continued Examination (RCE) Transmittal <input type="checkbox"/> Power of Attorney (Revocation of Prior Powers) <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Executed Declaration and Power of Attorney for Utility or Design Patent Application <input type="checkbox"/> Small Entity Statement <input type="checkbox"/> CD(s) for large table or computer program <input type="checkbox"/> Amendment After Allowance <input type="checkbox"/> Request for Certificate of Correction <input type="checkbox"/> Certificate of Correction (in duplicate)	<input type="checkbox"/> Notice of Appeal to Board of Patent Appeals and Interferences <input type="checkbox"/> Appeal Brief (in triplicate) <input type="checkbox"/> Status Inquiry <input checked="" type="checkbox"/> Return Receipt Postcard <input type="checkbox"/> Certificate of First Class Mailing under 37 C.F.R. 1.8 <input type="checkbox"/> Certificate of Facsimile Transmission under 37 C.F.R. 1.8 <input checked="" type="checkbox"/> Additional Enclosure(s) (please identify below) <ul style="list-style-type: none">• Form PTOL-85B• Transmittal of Issue Fee• Exhibit A• Check in the amount of \$1,700.00
---	---	--

CORRESPONDENCE ADDRESS

Direct all correspondence to: Patent Administrator
Kirkpatrick & Lockhart Nicholson
Graham LLP
75 State Street
Boston, MA 02109-1808
Tel. No.: (617) 261-3100
Fax No.: (617) 261-3175

SIGNATURE BLOCK

Date: January 13, 2006
Reg. No. 51,551
Tel. No.: (617) 261-3198
Fax No.: (617) 261-3175

Respectfully submitted,

Fangli Chen, Ph.D.
Agent for Applicants
Kirkpatrick & Lockhart
Nicholson Graham LLP
75 State Street
Boston, MA 02109-1808



PATENT
Atty. Docket No. STK-008CN

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S): Oppermann *et al.* CONFIRMATION NO.: 3498
SERIAL NO.: 09/754,831 GROUP NO.: 1646
FILING DATE: January 3, 2001 EXAMINER Kemmerer, Elizabeth
TITLE: Nucleic Acid Molecules Encoding Osteogenic Proteins

TRANSMITTAL OF ISSUE FEE

MAIL STOP ISSUE FEE
Commissioner for Patents
Alexandria, VA 22313-1450

Sir:

In response to the Notice of Allowance and Fee(s) Due mailed on October 18, 2005, attached please find:

- (a) Fee(s) Transmittal (Form PTOL-85B); and
- (b) a check in the amount of \$1,700.00 for payment of Issue Fee and Publication Fee.

Applicants notice that the Title of Invention is listed as "Osteogenic Devices" on the Notice of Allowance. Applicants submit that the title of invention was amended in the response filed on January 7, 2005, a copy of which is attached herewith as Exhibit A with relevant text highlighted. The amended title should read "Nucleic Acid Molecules Encoding Osteogenic Proteins." Accordingly, Applicants respectfully request that the Notice of Allowance be amended to reflect the correct title and the correct title "Nucleic Acid Molecules Encoding Osteogenic Proteins" be used on the issued patent.

Applicants believe no other fees are due with the submission of this paper. Should Applicants be in error, please consider this a conditional authorization to charge Deposit Account No. 50-1721.

Transmittal of Issue Fee
Application Serial No.: 09/754,831
Attorney Docket No.: STK-008CN
Page 2 of 2


The Examiner is invited to contact the undersigned to discuss any issues relating to the application.

Date: January 13, 2006
Reg. No. 51,551

Tel. No.: (617) 261-3198
Fax No.: (617) 261-3175
Customer Number: 022832

BOS-930594 v1

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'Fangli Chen', is written over a horizontal line.

Fangli Chen, Ph.D.

Agent for Applicants

Kirkpatrick & Lockhart Nicholson Graham LLP

75 State Street

Boston, Massachusetts 02109

Express Mail Mailing Label No. EV457083051US

COPY



PATENT

Attorney Docket No. STK-008CN

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Oppermann *et al.*

SERIAL NO.: 09/754,831 GROUP NO.: 1646

FILING DATE: January 3, 2001 EXAMINER: E. C. Kemmerer

TITLE: NUCLEIC ACID MOLECULES ENCODING OSTEOGENIC
PROTEINS (As Amended)

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

AMENDMENT AND RESPONSE

Dear Sir:

This paper is responsive to the Office action for the above-identified patent application, mailed from the U.S. Patent and Trademark Office on October 4, 2004. Applicants believe that no petition or fee is required for entry and consideration of this paper. If any petition or fee is required, please consider this a conditional petition for any required extension of time, and a conditional authorization to charge any required fee to Deposit Account No. 20-0531.

Amendments to the Specification begin on page 2 of this paper.

Amendments to the Claims are reflected in the listing of claims, which begins on page 4 of this paper.

Remarks begin on page 7 of this paper.

AMENDMENTS TO THE SPECIFICATION

On page 1, please delete the title "OSTEOGENIC DEVICES" and replace with the following title:

NUCLEIC ACID MOLECULES ENCODING OSTEOGENIC PROTEINS

On pages 9-11, please replace the paragraph starting with "In one preferred aspect" and ending with "such activity" with the following amended paragraph:

In one preferred aspect, these proteins comprise species of the generic amino acid sequences (SEQ ID NO: 3 and SEQ ID NO: 4, respectively):

```
1      10      20      30      40      50
      LXVXFDXGWXXWXXXPXGXXAXYCXGXCXXPXXXXXXXXNHAXX
      60      70      80      90     100
QXXVXXXNXXXXPXXCCXPXXXXXXXXLXXXXXXXXVXLXXYXXMXVXXCXCX
```

or

```
1      10      20      30      40      50
      CXXXXLXVXFDXGWXXWXXXPXGXXAXYCXGXCXXPXXXXXXXXNHAXX
      60      70      80      90     100
QXXVXXXNXXXXPXXCCXPXXXXXXXXLXXXXXXXXVXLXXYXXMXVXXCXCX
```

where the letters indicate the amino acid residues of standard single letter code, and the Xs represent amino acid residues. Preferred amino acid sequences within the foregoing generic sequences are (SEQ ID NO: 5 and SEQ ID NO: 6, respectively):

```
      10      20      30      40      50
      LYVDFRDVGWNDWIVAPPGYHAFYCHGECFPFLADHLNSTNHAIV
      K S S L  QE VIS E FD Y  E A AY MPESMKAS  VI
      F E K I  DN   L   N S  Q  ITK F P   TL
      A   S   K
      60      70      80      90     100
      QTLVNSVNP GKIPKACCVPTELSAISMLYLDENENVVLKNYQDMVVEGCGCR
SI HAI SEQV EP A EQMNSLAI FFNDQDK I RK EE T DA H H
      SI HAI SEQV EP A EQMNSLAI FFNDQDK I RK EE T DA H H
      RF   T   S   K DPV V   Y N S   H RN   RS
      N   S               K       P   E
```

and

	10		20		30		40		50														
CKRH	PLYV	DFRD	VGW	NDW	IVAP	PGYH	AFYCH	GEC	PFPLADH	LNSTN	HAI	IV											
RRRS	K	S	S	L	QE	VIS	E	FD	Y	E	A	AY	MPES	MKAS	VI								
	KE	F	E	K	I	DN		L		N	S	Q	ITK	F	P	TL							
	Q		A		S		K																
	60		70		80		90		100														
QTLV	NSV	NP	GK	IP	KAC	CV	PT	EL	SA	IS	ML	YLD	EN	ENV	VL	KNY	QDM	V	VEG	C	G	C	R
SI	HAI	SEQV	EP	A	EQM	NSLAI	FFND	QDK	I	RK	EE	T	DA	H	H								
SI	HAI	SEQV	EP	A	EQM	NSLAI	FFND	QDK	I	RK	EE	T	DA	H	H								
	RF		T	S		K	DPV	V	Y	N	S		H	RN	RS								
	N		S							K			P		E								

Wherein each of the amino acids arranged vertically at each position in the sequence may be used alternatively in various combinations. Note that these generic sequences have 6 and preferably 7 cysteine residues where inter- or intramolecular disulfide bonds can form, and contain other critical amino acids which influence the tertiary structure of the proteins. These generic structural features are found in previously published sequences, none of which have been described as capable of osteogenic activity, and most of which never have been linked with such activity.

AMENDMENTS TO THE CLAIMS

The following listing of claims replaces all prior versions of the claims pending in this application:

Listing of Claims

1-80. (Canceled).

81. (Previously presented) An isolated nucleic acid molecule comprising the nucleic acid sequence:

(a)

CTGTATGTCAGCTTCCGAGACCTGGGCTGGCAGGACTGGATCATCGCGCCTG
AAGGCTACGCGCGCTACTACTGTGAGGGGGAGTGTGCCTTCCCTCTGAACTC
CTACATGAACGCCACCAACCACGCCATCGTGCAGACGCTGGTCCACTTCATC
AACCCGGAAACGGTGCCCAAGCCCTGCTGTGCGCCACGCAGCTCAATGCCA
TCTCCGTCCTCTACTTCGATGACAGCTCCAACGTCATCCTGAAGAAATACAGA
AACATGGTGGTCCGGGCCTGTGGCTGCCACTAGCTCCT (nucleotides 16-314 of
SEQ ID NO: 42), or

(b) encoding an amino acid sequence:

LYVSFRDLGWQDWIIAPEGYAAYYCEGECAFLNSYMNATNHAIQTLV
HFINPETVPKPCCAPTQLNAISVLYFDDSSNVILKKYRNMVVRACGCH
(SEQ ID NO: 39), or a conservative amino acid variant thereof,

wherein said nucleic acid sequence encodes a protein competent to induce bone
and cartilage in a mammal.

82. (Previously presented) The isolated nucleic acid molecule of claim 81 comprising the nucleic acid sequence

TGTAAGAAGCACGAGCTGTATGTCAGCTTCCGAGACCTGGGCTGGCAGGACT
GGATCATCGCGCCTGAAGGCTACGCGCGCTACTACTGTGAGGGGGAGTGTGC
CTTCCCTCTGAACTCCTACATGAACGCCACCAACCACGCCATCGTGCAGACG

CTGGTCCACTTCATCAACCCGGAAACGGTGCCCAAGCCCTGCTGTGCGCCCA
CGCAGCTCAATGCCATCTCCGTCCTCTACTTCGATGACAGCTCCAACGTCATC
CTGAAGAAATACAGAAACATGGTGGTCCGGGCCTGTGGCTGCCACTAGCTCC
T (SEQ ID NO: 42),

or encoding an amino acid sequence:

CKKHELIVSFRDLGWQDWIIAPEGYAAYYCEGECAFLNSYMNATNHAIVQTL
VHFINPETVPKPCAPTQLNAISVLYFDDSSNVILKKYRNMVVRACGCH (amino
acids 6-107 of SEQ ID NO: 9).

83. (Currently amended) The isolated nucleic acid molecule of claim 81 or 82, wherein said protein competent to induce bone and cartilage further comprises
- (a) a pair of unglycosylated polypeptide chains, each of said unglycosylated polypeptide chains having a molecular weight of about 14 kDa to 16 kDa, as determined by polyacrylamide gel electrophoresis under reducing conditions; or
 - (b) an unglycosylated dimeric protein having a molecular weight of about 27 kDa, as determined by polyacrylamide gel electrophoresis under non-reducing conditions.
84. (Cancelled)
85. (Cancelled)
86. (Cancelled)
87. (Currently amended) An isolated host cell transformed with the nucleic acid molecule of ~~any one of claims 81, or 82, 84, 85, or 86.~~
88. (Currently amended) A ~~The~~ isolated host cell of claim 87, wherein said cell is a prokaryotic or an eukaryotic cell.
89. (Currently amended) The isolated host cell of claim 88, wherein said prokaryotic cell is an E.coli cell, and said eukaryotic cell is a Saccharomyces cell or a mammalian cell.
90. (Currently amended) The isolated nucleic acid molecule of any one of claims 81-~~86~~83, wherein the nucleic acid is DNA.

91. (Currently amended) The isolated host cell of any one of claims 87-89, wherein the nucleic acid is DNA.

REMARKS

Claims 81-83, 85, and 87-91 were pending in this application. Claims 84 and 86 were withdrawn from consideration as being directed to a non-elected invention. Claims 84, 85 and 86 are now cancelled without prejudice to Applicants' right to prosecute their subject matter in the present application and in related applications. Claims 83 and 87-91 are currently amended without any intent of disclaiming equivalents thereof. Accordingly, claims 81-83 and 87-91 are pending and presented for consideration.

Specification amendments

Applicants have amended the title to be indicative of the invention to which the pending claims are directed. In addition, Applicants have amended the specification to correct a handwritten notation and a typographical error. Support for the amendment is found in the specification at least, for example, at page 10, line 31, and at page 62, line 40. Applicants respectfully submit that the amendments to the specification introduce no new matter.

Claim amendments

Support for the amendment to claim 83 can be found in the specification as originally filed at least, for example, in the paragraph bridging pages 43 and 44, and in Figure 5 and accompanying text. Support for the amendment to claims 87-89 and 91 can be found in the specification as originally filed at least, for example, at page 60, the second paragraph. Claims 87, 88, 90 and 91 have also been amended to delete the reference to the cancelled claims and to correct informalities. Applicants respectfully submit that the amendments to the claims introduce no new matter.

Sequence Rules

The Office action objects to the application as being not fully in compliance with the sequence rules, 37 C.F.R. §§ 1.821-1.825. Specifically, the Office action alleges that the specification does not include sequence identifiers. Applicants submit that a Preliminary Amendment was filed on September 10, 2001, to introduce sequence identifiers into the specification. A copy of the Preliminary Amendment filed on September 10, 2001, is attached as

Exhibit A. Applicants respectfully request that the Preliminary Amendment of September 10, 2001, be entered and the objection be reconsidered and withdrawn.

Objection to the specification

The Office action objects to the specification for containing hand-written notations. The Office action also objects to the title of the invention for not being descriptive. Applicants have amended the specification and the title to overcome the objections. Accordingly, Applicants request reconsideration and withdrawal of the objection to the specification.

Claim objections

The Office action objects to claims 87-91 for depending from the non-elected inventions. Applicants have amended claims 87-91 to delete the reference to the non-elected inventions. Accordingly, Applicants request reconsideration and withdrawal of the objection to claims 87-91.

Claim Rejections Under 35 U.S.C. § 112, second paragraph

Claims 83, 85, 87-89 and 91 stand rejected under 35 U.S.C. § 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which Applicants regard as the invention.

Specifically, the Office action alleges that claim 83 fails to recite the method to determine the recited molecular weight. Claim 83 has been amended to recite “(a) a pair of unglycosylated polypeptide chains, each of said unglycosylated polypeptide chains having a molecular weight of about 14 kDa to 16 kDa, as determined by polyacrylamide gel electrophoresis under reducing conditions; or (b) an unglycosylated dimeric protein having a molecular weight of about 27 kDa, as determined by polyacrylamide gel electrophoresis under non-reducing conditions.” In view of the amendment, Applicants request reconsideration and withdrawal of the rejection of claim 83.

The Office action alleges that the recitation “consisting essentially of” in claim 85 is not clear. Without acquiescing to the merits of the rejection and in order to speed prosecution of this application, Applicants have cancelled claim 85. In view of the cancellation of claim 85, Applicants request reconsideration and withdrawal of the rejection of claim 85.

The Office action alleges that claims 87-89 and 91 are not clear in terms of whether the claims are directed to isolated host cells or host cells in the context of multi-cellular transgenic organisms, possibly even humans. Applicants have amended the claims to recite "isolated host cell." Accordingly, Applicants request reconsideration and withdrawal of the rejection of claims 87-89 and 91.

Double Patenting

Applicants request that all double patenting rejections be held in abeyance until the presence of otherwise-allowable subject matter is acknowledged.


CONCLUSION

Claims 81-83 and 87-91 are presently pending in this application. The Examiner is invited to contact the undersigned with any questions about this paper. Early and favorable action is respectfully solicited.

Date: January 7, 2005
Reg. No. 51,551

Tel. No.: (617) 310-8389
Fax No.: (617) 248-7100

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'Fangli Chen', written over a horizontal line.

Fangli Chen
Agent for Applicants
Testa, Hurwitz & Thibault, LLP
High Street Tower, 125 High Street
Boston, MA 02110